Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 5/2011

01-05-2011 | Original Paper

Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer

Authors: Astrid Enkelmann, Joana Heinzelmann, Ferdinand von Eggeling, Martina Walter, Alexander Berndt, Heiko Wunderlich, Kerstin Junker

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2011

Login to get access

Abstract

Purpose

Tumour development and progression are strongly affected by interaction of tumour cells and tumour stroma. Different tumour models demonstrate a supportive effect of tumour-associated fibroblasts (TAF) on the tumour genesis. Aims of the present study are the isolation of TAF from primary urinary bladder tumour specimens and the proteomic and epigenetic characterisation.

Methods

TAF were isolated from cultured urinary bladder tumour specimens. Therefore, primary tumour material was treated with EDTA followed by two separated detachment steps. Non-tumour fibroblasts were isolated from foreskin and normal bladder tissues. Proteins and total RNA were isolated from cultured fibroblasts. Protein pattern analyses were carried out by SELDI–TOF–MS. The miRNA expression profile was analysed by miRNA microarray.

Results

By optimising cell culture routines, we achieved to isolate and subsequently cultivate TAF from primary tumour material of the urinary bladder. SELDI–TOF–MS measurements reveal distinct differences in the proteomic patterns of TAF and non-tumour fibroblasts. Microarray analyses indicate specific expression of several miRNAs in TAF and non-tumour fibroblasts.

Conclusion

In summary, we determined proteomic and epigenetic differences between non-tumour fibroblasts and TAF of urinary bladder carcinoma and identified specific protein expression patterns as well as miRNA profiles of TAF in comparison with non-tumour fibroblasts. These findings provide more insights into the complex tumour network and a good starting point for the identification of markers for the prediction of tumour development and progression based on specific TAF expression patterns.
Appendix
Available only for authorised users
Literature
go back to reference Bar-Joseph Z, Siegfried Z, Brandeis M, Brors B, Lu Y, Eils R et al (2008) Genome-wide transcriptional analysis of the human cell cycle identifies genes differentially regulated in normal and cancer cells. Proc Nation Acad Sci 105:955–960CrossRef Bar-Joseph Z, Siegfried Z, Brandeis M, Brors B, Lu Y, Eils R et al (2008) Genome-wide transcriptional analysis of the human cell cycle identifies genes differentially regulated in normal and cancer cells. Proc Nation Acad Sci 105:955–960CrossRef
go back to reference Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–337PubMedCrossRef Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–337PubMedCrossRef
go back to reference Busch A, Michel S, Hoppe C, Driesch D, Claussen U, von Eggeling F (2005) Proteome analysis of maternal serum samples for trisomy 21 pregnancies using proteinchip arrays and bioinformatics. J Histochem Cytochem 53:341–343PubMedCrossRef Busch A, Michel S, Hoppe C, Driesch D, Claussen U, von Eggeling F (2005) Proteome analysis of maternal serum samples for trisomy 21 pregnancies using proteinchip arrays and bioinformatics. J Histochem Cytochem 53:341–343PubMedCrossRef
go back to reference Cattan N, Rochet N, Mazeau C, Zanghellini E, Mari B, Chauzy C et al (2001) Establishment of two new human bladder carcinoma cell lines, CAL 29 and CAL 185. Comparative study of cell scattering and epithelial to mesenchyme transition induced by growth factors. Br J Cancer 85:1412–1417PubMedCrossRef Cattan N, Rochet N, Mazeau C, Zanghellini E, Mari B, Chauzy C et al (2001) Establishment of two new human bladder carcinoma cell lines, CAL 29 and CAL 185. Comparative study of cell scattering and epithelial to mesenchyme transition induced by growth factors. Br J Cancer 85:1412–1417PubMedCrossRef
go back to reference Cummins JM, Velculescu VE (2006) Implications of micro-RNA profiling for cancer diagnosis. Oncogene 25:6220–6227PubMedCrossRef Cummins JM, Velculescu VE (2006) Implications of micro-RNA profiling for cancer diagnosis. Oncogene 25:6220–6227PubMedCrossRef
go back to reference Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R et al (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69:4851–4860PubMedCrossRef Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R et al (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69:4851–4860PubMedCrossRef
go back to reference Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRef Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRef
go back to reference Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518–527PubMedCrossRef Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518–527PubMedCrossRef
go back to reference Hu M, Polyak K (2008) Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18:27–34PubMedCrossRef Hu M, Polyak K (2008) Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18:27–34PubMedCrossRef
go back to reference Iorio MV, Ferracin M, Liu C-G, Veronese A, Spizzo R, Sabbioni S et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065–7070PubMedCrossRef Iorio MV, Ferracin M, Liu C-G, Veronese A, Spizzo R, Sabbioni S et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065–7070PubMedCrossRef
go back to reference Knowles MA (2006) Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27:361–373PubMedCrossRef Knowles MA (2006) Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27:361–373PubMedCrossRef
go back to reference Kunz-Schughart LA, Knuechel R (2002) Tumor-associated fibroblasts (part I): active stromal participants in tumor development and progression? Histol Histopathol 17:599–621PubMed Kunz-Schughart LA, Knuechel R (2002) Tumor-associated fibroblasts (part I): active stromal participants in tumor development and progression? Histol Histopathol 17:599–621PubMed
go back to reference Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N et al (2009) Epigenetic silencing of microRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 9:293–301PubMedCrossRef Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N et al (2009) Epigenetic silencing of microRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 9:293–301PubMedCrossRef
go back to reference Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838PubMedCrossRef Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838PubMedCrossRef
go back to reference Mueller MM, Fusenig NE (2004) Friends or foes [mdash] bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4:839–849PubMedCrossRef Mueller MM, Fusenig NE (2004) Friends or foes [mdash] bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4:839–849PubMedCrossRef
go back to reference Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ Jr, Yokota SJ, Bankert RB (2007) Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol 178:5552–5562PubMed Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ Jr, Yokota SJ, Bankert RB (2007) Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol 178:5552–5562PubMed
go back to reference Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S et al (2008) A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 28:39–48 Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S et al (2008) A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 28:39–48
go back to reference Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA (2009) MicroRNAs [mdash] the micro steering wheel of tumour metastases. Nat Rev Cancer 9:293–302PubMedCrossRef Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA (2009) MicroRNAs [mdash] the micro steering wheel of tumour metastases. Nat Rev Cancer 9:293–302PubMedCrossRef
go back to reference Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59:5002–5011PubMed Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59:5002–5011PubMed
go back to reference Östman A, Augsten M (2009) Cancer-associated fibroblasts and tumor growth–bystanders turning into key players. Curr Opin Genet Dev 19:67–73PubMedCrossRef Östman A, Augsten M (2009) Cancer-associated fibroblasts and tumor growth–bystanders turning into key players. Curr Opin Genet Dev 19:67–73PubMedCrossRef
go back to reference Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M et al (2008) No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 40:650–655PubMedCrossRef Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M et al (2008) No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 40:650–655PubMedCrossRef
go back to reference Ruault M, van der Bruggen P, Brun ME, Boyle S, Roizes G, De Sario A (2002) New BAGE (B melanoma antigen) genes mapping to the juxtacentromeric regions of human chromosomes 13 and 21 have a cancer/testis expression profile. Eur J Hum Genet 10:833–840PubMedCrossRef Ruault M, van der Bruggen P, Brun ME, Boyle S, Roizes G, De Sario A (2002) New BAGE (B melanoma antigen) genes mapping to the juxtacentromeric regions of human chromosomes 13 and 21 have a cancer/testis expression profile. Eur J Hum Genet 10:833–840PubMedCrossRef
go back to reference Rumpold H, Mascher K, Untergasser G, Plas E, Hermann M, Berger P (2002) Trans-differentiation of prostatic stromal cells leads to decreased glycoprotein hormone alpha production. J Clin Endocrinol Metab 87:5297–5303PubMedCrossRef Rumpold H, Mascher K, Untergasser G, Plas E, Hermann M, Berger P (2002) Trans-differentiation of prostatic stromal cells leads to decreased glycoprotein hormone alpha production. J Clin Endocrinol Metab 87:5297–5303PubMedCrossRef
go back to reference Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L et al (2008) Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68:6416–6424PubMedCrossRef Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L et al (2008) Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68:6416–6424PubMedCrossRef
go back to reference Seifert HH, Meyer A, Cronauer MV, Hatina J, Muller M, Rieder H et al (2007) A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. World J Urol 25:297–302PubMedCrossRef Seifert HH, Meyer A, Cronauer MV, Hatina J, Muller M, Rieder H et al (2007) A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. World J Urol 25:297–302PubMedCrossRef
go back to reference Sorrentino A, Liu C-G, Addario A, Peschle C, Scambia G, Ferlini C (2008) Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111:478–486PubMedCrossRef Sorrentino A, Liu C-G, Addario A, Peschle C, Scambia G, Ferlini C (2008) Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111:478–486PubMedCrossRef
go back to reference Uchiyama S, Itoh H, Naganuma S, Nagaike K, Fukushima T, Tanaka H et al (2007) Enhanced expression of hepatocyte growth factor activator inhibitor type 2-related small peptide at the invasive front of colon cancers. Gut 56:215–226PubMedCrossRef Uchiyama S, Itoh H, Naganuma S, Nagaike K, Fukushima T, Tanaka H et al (2007) Enhanced expression of hepatocyte growth factor activator inhibitor type 2-related small peptide at the invasive front of colon cancers. Gut 56:215–226PubMedCrossRef
go back to reference Urbich C, Kuehbacher A, Dimmeler S (2008) Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 79:581–588PubMedCrossRef Urbich C, Kuehbacher A, Dimmeler S (2008) Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 79:581–588PubMedCrossRef
go back to reference Wang X, Tang S, Le S-Y, Lu R, Rader JS, Meyers C et al (2008) Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 3:e2557PubMedCrossRef Wang X, Tang S, Le S-Y, Lu R, Rader JS, Meyers C et al (2008) Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 3:e2557PubMedCrossRef
go back to reference Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V et al (2001) A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15:837–846PubMedCrossRef Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V et al (2001) A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15:837–846PubMedCrossRef
go back to reference Yang G, Rosen DG, Zhang Z, Bast RC, Mills GB, Colacino JA et al (2006) The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Nation Acad Sci 103:16472–16477CrossRef Yang G, Rosen DG, Zhang Z, Bast RC, Mills GB, Colacino JA et al (2006) The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Nation Acad Sci 103:16472–16477CrossRef
go back to reference Zhang B, Pan X, Cobb GP, Anderson TA (2007) MicroRNAs as oncogenes and tumor suppressors. Dev Biol 302:1–12PubMedCrossRef Zhang B, Pan X, Cobb GP, Anderson TA (2007) MicroRNAs as oncogenes and tumor suppressors. Dev Biol 302:1–12PubMedCrossRef
go back to reference Zhang C, Fu L, Fu J, Hu L, Yang H, Rong T-H et al (2009) Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res 15:4017–4027PubMedCrossRef Zhang C, Fu L, Fu J, Hu L, Yang H, Rong T-H et al (2009) Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res 15:4017–4027PubMedCrossRef
go back to reference Zhong L, Roybal J, Chaerkady R, Zhang W, Choi K, Alvarez CA et al (2008) Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res 68:7237–7245PubMedCrossRef Zhong L, Roybal J, Chaerkady R, Zhang W, Choi K, Alvarez CA et al (2008) Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res 68:7237–7245PubMedCrossRef
Metadata
Title
Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer
Authors
Astrid Enkelmann
Joana Heinzelmann
Ferdinand von Eggeling
Martina Walter
Alexander Berndt
Heiko Wunderlich
Kerstin Junker
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 5/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0932-6

Other articles of this Issue 5/2011

Journal of Cancer Research and Clinical Oncology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.